J P M O R G A N Europe Equity Research 24 June 2026 Argenx Takeaways from the Myositis R&D Spotlight session Yesterday we attended the R&D spotlight session for Autoimmune Myositis in Boston. Here, Argenx disclosed further information regarding the subgroup patient population in the Phase II trial, where IMNM patients constituted c.60% of patients and demonstrated a statistically significant result in this subgroup alone, and DM patients (c.30% of patients) also showed a clear signal of efficacy, albeit wit ...